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Abstract
Orbital apex metastasis from adenoid cystic carcinoma (ACC) is rare. We present a patient with
known metastatic ACC presented with a rapidly declining vision with visual acuity oculus
dexter (OD) equal to counting fingers at two feet. On imaging, she was found to have a right
orbital apex tumor causing compressive optic neuropathy. She received the intensity modulated
radiation therapy (IMRT). After completion of the therapy, she had regained essentially a full
vision with visual acuity OD of 20/30 without corrective lenses. The treatment rationale and
pertinent literature are discussed in this article.
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Introduction And Background
Visual loss due to extraocular orbital metastases is a relatively uncommon [1] and devastating
complication of malignancy. The adenoid cystic carcinoma (ACC) is an uncommon malignancy
which arises within secretory glands, most commonly of the head and neck [2]. It typically has a
relatively indolent but relentless course [2]. In this review, we report the case of a 58-year-old
female with the clinical history of cavernous sinus and right temporal lobe metastases, who
presented with acute right visual loss due to compressive optic neuropathy. She received
radiotherapy with subsequent recovery of vision. We also review the current literature regarding
the treatment of ACC metastases with radiotherapy and the use of radiotherapy in orbital
metastases.
Review
Case presentation
A 58-year-old Caucasian female presented in April 2012 with new onset right parasthesias in
the ophthalmic nerve (V1), the maxillary nerve (V2) and the mandibular nerve (V3)
distributions with associated neuralgia. The magnetic resonance imaging (MRI) revealed a right
cavernous sinus mass lesion. At an outside institution, the patient underwent partial resection.
The pathology revealed ACC with perineural invasion. The staging positron emission
tomography (PET) and biopsy revealed the site of primary in the right lateral wall of the
nasopharynx. The patient was treated with the stereotactic body radiation therapy (SBRT)
on Cyberknife ™ receiving 3750 centi-Gray (cGy) in five fractions of 750 cGy per fraction
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(Figure 1) to both areas of disease, completed the treatment in August 2012. Post-treatment,
her pain abated, but the facial paresthesias persisted. Her vision was normal. The follow-up
MRI in September 2014 revealed a new 4 mm area of enhancement in the medial right temporal
lobe. This was clinically asymptomatic. The new area was followed by serial MRIs, which
showed slow progression, evolving into two adjacent areas of enhancement. These two new
areas were treated with the hypo-fractionated radiotherapy on Cyberknife® receiving 4000 cGy
in 10 fractions of 400 cGy per fraction (Figure 2), completed in October 2015.
FIGURE 1: The stereotactic body radiation therapy treatment
plan for the primary tumor site in the nasopharynx.
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FIGURE 2: The hypofractionated radiotherapy treatment plan
for new metastases.
In August 2016, the patient presented with blurred vision in the right eye, which was further
assessed by the ophthalmology and felt to be secondary to cataracts. The follow-up MRI at that
time was stable. She underwent cataract removal in September 2016. Following the surgery, the
patient reported progressive right visual loss with orbital and retro-orbital pain. On
examination during October 2016, the patient had a fixed right pupil with the blurred vision of
the right eye. She was only able to discern the objects and was not able to read the written
words. Due to the concern of possible radiation-induced optic neuropathy (RION), she was
initiated on high dose methylprednisolone 1000 g IV QD X three days and pentoxifylline 400 mg
TID with vitamin E 1000 IU daily as per publications for the treatment of RION [3]. After day
two of intravenous (IV) steroids, the patient’s pain resolved and the right pupil became
reactive. However, the vision remained unchanged. The MRI revealed a right orbital apex tumor
consistent with metastasis causing compressive optic neuropathy (Figure 3).
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FIGURE 3: The magnetic resonance imaging of the orbital
metastases causing compressive neuropathy.
The patient was evaluated by the neurosurgery, ophthalmology, and neuro-ophthalmology at
outside centers and no surgical intervention was recommended. The patient was started on
dexamethasone 4 mg twice a day and received a third course of the radiation therapy on
Cyberknife®. The dose delivered was 5000 cGy in 25 fractions of 200 cGy per day utilizing the
intensity-modulated radiation therapy (IMRT) prescribed to the 80% isodose line, which
covered 95% of the planning tumor volume (PTV) and 99% of the gross tumor volume (GTV)
(Figure 4). The MIM ™ fusion (MIM Software, Cleveland, Ohio, United States of America) was
performed for the previous treatments, and previous maximum cumulative doses to critical
structures were reviewed; critical structures included the brainstem, optic chiasm, and the
optic nerves (Figure 5). The patient completed the treatment in December 2016. At the time of
completion, her vision was clinically restored and the ophthalmologic examination revealed OD
of 20/30. She had been for follow-up in June 2017. The repeat MRI at that time showed stable
disease and the ophthalmologic testing revealed 20/30 in the affected eye. As of November
2017, her visual recovery was stable.
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FIGURE 4: The intensity modulated radiation therapy treatment
plan for the orbital metastasis.
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FIGURE 5: The computed tomography and the magnetic
resonance imaging fusion of the orbital metastasis.
Discussion
Review of the Metastatic ACC and the Current Treatment Strategies
The ACC has been relatively rare, yet locally aggressive cancer of the major and minor salivary
glands [2]. It is characterized by an indolent course, with the high incidence of late local
recurrence and distant metastases [2]. The most common sites of metastasis in ACC are the
lungs, bone, and liver [4-5]; however, the intracranial metastases are not uncommon, with
various studies reporting incidence from 4% to 22% [6]. This is most likely due to the tumor’s
propensity for perineural invasion and spread along nerves [7]. Although metastases are
common in this tumor, the ACC metastases to the orbit are exceedingly rare. To our knowledge,
there has been only one other reported case of ACC metastases to the orbit [8]. The ACC
primaries in the orbit are also rare, accounting for 1% of the orbital tumors [9]. These orbital
tumors generally arise from the lacrimal gland tissue; however, there have been cases of the
ACC primaries in the orbit that was not of lacrimal gland origin [9-13].
Currently, the mainstay of the treatment for primary ACC and local tumor recurrence consists
of the radical excision with or without postoperative radiation using the external beam
radiation therapy (EBRT) [5, 14]. There is some controversy in the literature regarding the role
of the postoperative radiation in the treatment of ACC, but it is widely recommended due to the
high incidence of recurrence [15]. When possible, the surgery and post-operative radiation
continue to be the treatment of choice for metastases as well. With the surgery and adjuvant
radiation, five-year survival is high, reported at between 64% and 95% [4-5, 15-17]. However,
these numbers dwindle with time. A Danish study by Bjorndal, et al. reported a 15-year
recurrence-free survival rate at 55% [4]. Another study performed by He, et al. reported a 10-
year disease-free survival rate at 23% [15].
The surgical excision in this area was deemed to be risky due to the proximity of the tumor to
the optic nerve. The alternatives to the surgery include the radiation therapy and
chemotherapy. The role of chemotherapy in the management of the ACC metastases has been
extensively studied, but there remains a lack of significant data regarding its usefulness [5]. In
some studies, it has shown to be effective in treating symptoms of ACC metastases [18].
However, the chemotherapeutic agents to date have not shown any benefit in long-term
survival rates for the metastatic ACC [18]. 
In terms of the radiation, common modalities include the EBRT, IMRT, volumetric modulated
arc radiation therapy, stereotactic radiosurgery, particle radiation therapy, and brachytherapy.
Of these modalities, the EBRT remains the mainstay of the treatment for the ACC [14]. Non-
operative therapy with photon irradiation has a reported cure rate of 20% [19]. However, it has
an increased incidence of local failure in comparison to combined modality treatment and is
therefore generally reserved for the patients who are not surgical candidates or have
unresectable tumors [19]. Ko, et al. reported three-year disease-free survival rates for
individuals who received photon radiotherapy alone versus radiotherapy with surgery as 18.3%
compared to 67.3%, respectively [16]. The subsequent disease-free survival rate for the
radiotherapy alone group dropped to 9.2% at the five-year mark [16]. The IMRT is a form of
EBRT that allows the radiation to be delivered at higher doses and with greater conformality as
compared to the traditional EBRT [14]. This is especially beneficial when treating tumors
located adjacent to radiosensitive structures, such as the orbit [14]. However, to our knowledge,
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the efficacy of the IMRT in relation to traditional EBRT for the treatment of ACC is yet to be
studied. 
Particle irradiation has also been studied in treating salivary gland tumors. The fast neutron
radiotherapy treatment of salivary gland tumors was compared to conventional photon and/or
electron radiotherapy in terms of efficacy in the Radiation Therapy Oncology Group-Medical
Research Council (RTOG-MRC) randomized trial [20]. The study found that fast neutron
radiotherapy was superior to photon radiotherapy in local control rates: 67% for the neutron
radiotherapy and only 17% for the photon radiotherapy [20]. However, there was no
improvement in survival rates with neutron therapy, and the follow up final report of the
RTOG-MRC revealed that neutron therapy resulted in more severe toxicity than photon therapy
[20-21]. Takagi, et al. studied the efficacy of treating unresectable or the grade 4 ACC’s of the
head and neck with the proton or carbon ion radiation. Five-year local control rates were 66% in
unresectable tumors and 68% in grade 4 ACC’s [22]. However, similar to neutron therapy, 26%
of the patients treated with protons or carbon ions experienced grade 3 or greater late toxicities
[22]. In addition to unchanged survival rates and increased toxicity, there remains a paucity of
particle therapy centers in the country, making access to particle therapies difficult for both the
patients and practitioners.
Implications of this Case in the Intensity Modulated Radiation Therapy Treatment of the Adenoid
Cystic Carcinoma and Orbital Tumors
In this case, the patient with a known history of ACC metastases of the cavernous sinus and
right temporal region presented with an ACC metastasis to the right orbital apex causing
compressive optic neuropathy. The surgical excision in this area was deemed to be risky due to
the proximity of the tumor to the optic nerve. Based on the extent of this patient’s visual loss,
its effect on the quality of life, and the previous response of her metastases to the radiation
therapy, we treated the gross tumor with radiation in an attempt to control the tumor and
salvage of her vision as much as possible. As opposed to the EBRT, conventional fractionated
IMRT via Cyberknife ™ was used due to the proximity of the tumor to the optic nerves and the
risk of toxicity to the other surrounding orbital structures. During the treatment, she
experienced no adverse effects and since has experienced no late-term toxicity as a result of the
treatment. As of November 2017, she has had complete recovery of the vision. We were unable
to find similar cases of complete visual recovery following the radiation treatment of the ACC
metastases to the orbit. Therefore, this case demonstrates the efficacy of the IMRT in the
treatment of the ACC metastases.
In a broader sense, this case also shows the efficacy of the IMRT in the treatment of orbital apex
tumors. The orbit is a complex space with critical structures, including the optic nerve. This
provides a uniquely challenging situation for the medical practitioners. The treatment is often
multidisciplinary, especially in the treatment of metastatic orbital tumors [23]. The surgery is a
common option for the treatment of orbital tumors; however, it is often difficult and risky due
to the complex anatomy and dense network of critical neurovascular structures held within the
orbit [24]. As an alternative to surgery, the radiation is a valid treatment option for orbital
tumors. The EBRT has long been a mainstay of the treatment for orbital tumors [25]. However,
the dose to the surrounding structures within the orbit is generally the same as to the target
tissue, leading to significant side effects associated with this modality, namely dry eye, eyelash
loss, cataract, neovascular glaucoma, radiation retinopathy, and optic neuropathy [14, 25]. As
previously stated, the IMRT is more conformal than conventional EBRT, thereby decreasing the
radiation dose too close critical structures [25]. With the precision of IMRT, we were able to
treat the orbit and achieve near complete recovery of vision with no side effects. We, therefore,
present the IMRT as a superior modality to the traditional EBRT in the treatment of orbital
tumors.
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Conclusions
In this study, we present a case of nasopharyngeal ACC primary metastasizing to the orbital
apex, a location in which, to our knowledge, only one other study has reported metastatic
involvement. In addition, we present a case of symptomatic relief of compressive optic
neuropathy with the use of radiation therapy (using IMRT modality) without surgery. We
contend that metastases to the orbit in individuals with the history of the ACC should be
included in the differential diagnosis when presenting an orbital mass. In addition, we present
IMRT as an effective palliative treatment for the ACC and orbital tumors as a whole.
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